CA2579859C - Decreasing potential iatrogenic risks associated with influenza vaccines - Google Patents
Decreasing potential iatrogenic risks associated with influenza vaccines Download PDFInfo
- Publication number
- CA2579859C CA2579859C CA2579859A CA2579859A CA2579859C CA 2579859 C CA2579859 C CA 2579859C CA 2579859 A CA2579859 A CA 2579859A CA 2579859 A CA2579859 A CA 2579859A CA 2579859 C CA2579859 C CA 2579859C
- Authority
- CA
- Canada
- Prior art keywords
- vaccine
- virus
- influenza
- culture
- grow
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 229960003971 influenza vaccine Drugs 0.000 title claims description 37
- 230000000642 iatrogenic effect Effects 0.000 title description 3
- 230000003247 decreasing effect Effects 0.000 title description 2
- 229960005486 vaccine Drugs 0.000 claims abstract description 101
- 241000700605 Viruses Species 0.000 claims abstract description 66
- 210000004027 cell Anatomy 0.000 claims abstract description 62
- 238000012360 testing method Methods 0.000 claims abstract description 48
- 238000000034 method Methods 0.000 claims abstract description 47
- 244000052769 pathogen Species 0.000 claims abstract description 40
- 235000013601 eggs Nutrition 0.000 claims abstract description 34
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 29
- 238000004519 manufacturing process Methods 0.000 claims abstract description 25
- 210000004962 mammalian cell Anatomy 0.000 claims abstract description 24
- 238000004113 cell culture Methods 0.000 claims abstract description 18
- 230000008569 process Effects 0.000 claims description 26
- 210000003501 vero cell Anatomy 0.000 claims description 21
- 238000001514 detection method Methods 0.000 claims description 19
- 239000012678 infectious agent Substances 0.000 claims description 19
- 230000003612 virological effect Effects 0.000 claims description 17
- 241000709661 Enterovirus Species 0.000 claims description 12
- 238000003757 reverse transcription PCR Methods 0.000 claims description 11
- 241000271566 Aves Species 0.000 claims description 9
- 241000702247 Reoviridae Species 0.000 claims description 9
- 241000709664 Picornaviridae Species 0.000 claims description 8
- 241000725643 Respiratory syncytial virus Species 0.000 claims description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 8
- 230000002779 inactivation Effects 0.000 claims description 7
- 102000039446 nucleic acids Human genes 0.000 claims description 6
- 108020004707 nucleic acids Proteins 0.000 claims description 6
- 150000007523 nucleic acids Chemical class 0.000 claims description 6
- 241001533384 Circovirus Species 0.000 claims description 5
- 241000712079 Measles morbillivirus Species 0.000 claims description 5
- 208000002606 Paramyxoviridae Infections Diseases 0.000 claims description 5
- 241000125945 Protoparvovirus Species 0.000 claims description 5
- 241000702670 Rotavirus Species 0.000 claims description 5
- 239000002671 adjuvant Substances 0.000 claims description 5
- 238000002156 mixing Methods 0.000 claims description 5
- 229940031418 trivalent vaccine Drugs 0.000 claims description 5
- 238000002965 ELISA Methods 0.000 claims description 4
- 241000711504 Paramyxoviridae Species 0.000 claims description 4
- 238000002347 injection Methods 0.000 claims description 4
- 239000007924 injection Substances 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims description 4
- 239000003755 preservative agent Substances 0.000 claims description 4
- 241000712045 Morbillivirus Species 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 3
- 230000000984 immunochemical effect Effects 0.000 claims description 3
- 230000002335 preservative effect Effects 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 229940031626 subunit vaccine Drugs 0.000 claims description 3
- 241000700586 Herpesviridae Species 0.000 claims description 2
- 241000829111 Human polyomavirus 1 Species 0.000 claims description 2
- 241000701460 JC polyomavirus Species 0.000 claims description 2
- 108010052285 Membrane Proteins Proteins 0.000 claims description 2
- 102000018697 Membrane Proteins Human genes 0.000 claims description 2
- 241000204031 Mycoplasma Species 0.000 claims description 2
- 241000711904 Pneumoviridae Species 0.000 claims description 2
- 208000036142 Viral infection Diseases 0.000 claims description 2
- 230000002238 attenuated effect Effects 0.000 claims description 2
- 238000010790 dilution Methods 0.000 claims description 2
- 239000012895 dilution Substances 0.000 claims description 2
- 238000003306 harvesting Methods 0.000 claims description 2
- 238000011081 inoculation Methods 0.000 claims description 2
- 238000004806 packaging method and process Methods 0.000 claims description 2
- 238000000751 protein extraction Methods 0.000 claims description 2
- 230000009385 viral infection Effects 0.000 claims description 2
- 229960000172 trivalent influenza vaccine Drugs 0.000 claims 1
- 238000011109 contamination Methods 0.000 abstract description 16
- 206010064091 Iatrogenic infection Diseases 0.000 abstract 1
- 238000003556 assay Methods 0.000 description 16
- 241000702244 Orthoreovirus Species 0.000 description 11
- 239000000463 material Substances 0.000 description 10
- 238000003908 quality control method Methods 0.000 description 10
- 239000000758 substrate Substances 0.000 description 10
- 241000701085 Human alphaherpesvirus 3 Species 0.000 description 9
- 241001505332 Polyomavirus sp. Species 0.000 description 8
- 239000000427 antigen Substances 0.000 description 7
- 108091007433 antigens Proteins 0.000 description 7
- 102000036639 antigens Human genes 0.000 description 7
- 239000003795 chemical substances by application Substances 0.000 description 7
- 241000702626 Infectious bursal disease virus Species 0.000 description 6
- 206010022000 influenza Diseases 0.000 description 6
- 238000002360 preparation method Methods 0.000 description 6
- 244000309467 Human Coronavirus Species 0.000 description 5
- 241000342334 Human metapneumovirus Species 0.000 description 5
- 241000702263 Reovirus sp. Species 0.000 description 5
- 241000315672 SARS coronavirus Species 0.000 description 5
- 239000003599 detergent Substances 0.000 description 5
- 241000701161 unidentified adenovirus Species 0.000 description 5
- 241000701931 Canine parvovirus Species 0.000 description 4
- 241000598171 Human adenovirus sp. Species 0.000 description 4
- 241000701074 Human alphaherpesvirus 2 Species 0.000 description 4
- 241000711920 Human orthopneumovirus Species 0.000 description 4
- 241000710799 Rubella virus Species 0.000 description 4
- 241000700584 Simplexvirus Species 0.000 description 4
- 241000709710 Swine vesicular disease virus Species 0.000 description 4
- 229960000074 biopharmaceutical Drugs 0.000 description 4
- 230000000241 respiratory effect Effects 0.000 description 4
- 241000701242 Adenoviridae Species 0.000 description 3
- 241001516406 Avian orthoreovirus Species 0.000 description 3
- 241000606161 Chlamydia Species 0.000 description 3
- 241000709687 Coxsackievirus Species 0.000 description 3
- 241000700588 Human alphaherpesvirus 1 Species 0.000 description 3
- 241001631648 Polyomaviridae Species 0.000 description 3
- 241000202347 Porcine circovirus Species 0.000 description 3
- 108700010877 adenoviridae proteins Proteins 0.000 description 3
- 230000008859 change Effects 0.000 description 3
- 239000000356 contaminant Substances 0.000 description 3
- 238000003753 real-time PCR Methods 0.000 description 3
- 230000001105 regulatory effect Effects 0.000 description 3
- 230000002441 reversible effect Effects 0.000 description 3
- 241000283690 Bos taurus Species 0.000 description 2
- 241000711895 Bovine orthopneumovirus Species 0.000 description 2
- 241000282552 Chlorocebus aethiops Species 0.000 description 2
- 241000711573 Coronaviridae Species 0.000 description 2
- 229940046168 CpG oligodeoxynucleotide Drugs 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- 241001466953 Echovirus Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 241000287828 Gallus gallus Species 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 241001207270 Human enterovirus Species 0.000 description 2
- 241000712431 Influenza A virus Species 0.000 description 2
- 241000713196 Influenza B virus Species 0.000 description 2
- 241000829100 Macaca mulatta polyomavirus 1 Species 0.000 description 2
- 241000711386 Mumps virus Species 0.000 description 2
- 108091005804 Peptidases Proteins 0.000 description 2
- 241000711902 Pneumovirus Species 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 102000004142 Trypsin Human genes 0.000 description 2
- 108090000631 Trypsin Proteins 0.000 description 2
- 239000000839 emulsion Substances 0.000 description 2
- 208000037797 influenza A Diseases 0.000 description 2
- 210000003734 kidney Anatomy 0.000 description 2
- 239000002609 medium Substances 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 230000010076 replication Effects 0.000 description 2
- 239000012679 serum free medium Substances 0.000 description 2
- 239000004017 serum-free culture medium Substances 0.000 description 2
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 2
- 239000012588 trypsin Substances 0.000 description 2
- 241000990167 unclassified Simian adenoviruses Species 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108010042708 Acetylmuramyl-Alanyl-Isoglutamine Proteins 0.000 description 1
- 241000008921 Avian coronavirus Species 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 241000702628 Birnaviridae Species 0.000 description 1
- 240000005589 Calophyllum inophyllum Species 0.000 description 1
- 241000282465 Canis Species 0.000 description 1
- LZZYPRNAOMGNLH-UHFFFAOYSA-M Cetrimonium bromide Chemical compound [Br-].CCCCCCCCCCCCCCCC[N+](C)(C)C LZZYPRNAOMGNLH-UHFFFAOYSA-M 0.000 description 1
- 201000006082 Chickenpox Diseases 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 241001647372 Chlamydia pneumoniae Species 0.000 description 1
- 241001647378 Chlamydia psittaci Species 0.000 description 1
- 241000606153 Chlamydia trachomatis Species 0.000 description 1
- 108010061994 Coronavirus Spike Glycoprotein Proteins 0.000 description 1
- 241000709675 Coxsackievirus B3 Species 0.000 description 1
- 241000709711 Coxsackievirus B5 Species 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 102000016911 Deoxyribonucleases Human genes 0.000 description 1
- 108010053770 Deoxyribonucleases Proteins 0.000 description 1
- 241000709638 Echovirus E6 Species 0.000 description 1
- 241000588724 Escherichia coli Species 0.000 description 1
- 241000711467 Human coronavirus 229E Species 0.000 description 1
- 241000702617 Human parvovirus B19 Species 0.000 description 1
- 241000726041 Human respirovirus 1 Species 0.000 description 1
- 241000712003 Human respirovirus 3 Species 0.000 description 1
- 241000430519 Human rhinovirus sp. Species 0.000 description 1
- 241001559187 Human rubulavirus 2 Species 0.000 description 1
- 208000004467 Infectious Canine Hepatitis Diseases 0.000 description 1
- 102000008072 Lymphokines Human genes 0.000 description 1
- 108010074338 Lymphokines Proteins 0.000 description 1
- 241001480506 Mammalian orthoreovirus 2 Species 0.000 description 1
- 241000351643 Metapneumovirus Species 0.000 description 1
- 241000702623 Minute virus of mice Species 0.000 description 1
- 241000202938 Mycoplasma hyorhinis Species 0.000 description 1
- 241000202934 Mycoplasma pneumoniae Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101710163270 Nuclease Proteins 0.000 description 1
- 108010058846 Ovalbumin Proteins 0.000 description 1
- 238000002944 PCR assay Methods 0.000 description 1
- 241000711502 Paramyxovirinae Species 0.000 description 1
- 241000701945 Parvoviridae Species 0.000 description 1
- 102000035195 Peptidases Human genes 0.000 description 1
- 108010081690 Pertussis Toxin Proteins 0.000 description 1
- 229940124867 Poliovirus vaccine Drugs 0.000 description 1
- 108010076039 Polyproteins Proteins 0.000 description 1
- 241000702619 Porcine parvovirus Species 0.000 description 1
- 208000024777 Prion disease Diseases 0.000 description 1
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 1
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 1
- 206010057190 Respiratory tract infections Diseases 0.000 description 1
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 description 1
- 241000219061 Rheum Species 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 241001533467 Rubulavirus Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 241000701093 Suid alphaherpesvirus 1 Species 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 241000710924 Togaviridae Species 0.000 description 1
- 241000700618 Vaccinia virus Species 0.000 description 1
- 206010046980 Varicella Diseases 0.000 description 1
- 241001494970 Vesicular exanthema of swine virus Species 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 206010003246 arthritis Diseases 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 238000003501 co-culture Methods 0.000 description 1
- 238000003271 compound fluorescence assay Methods 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 229940009976 deoxycholate Drugs 0.000 description 1
- KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 239000003596 drug target Substances 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 229940035423 ethyl ether Drugs 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000002866 fluorescence resonance energy transfer Methods 0.000 description 1
- 230000002068 genetic effect Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000010544 human prion disease Diseases 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 238000002649 immunization Methods 0.000 description 1
- 230000002163 immunogen Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000001524 infective effect Effects 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 238000007403 mPCR Methods 0.000 description 1
- 210000001161 mammalian embryo Anatomy 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- QSHDDOUJBYECFT-UHFFFAOYSA-N mercury Chemical compound [Hg] QSHDDOUJBYECFT-UHFFFAOYSA-N 0.000 description 1
- 229910052753 mercury Inorganic materials 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 229940035032 monophosphoryl lipid a Drugs 0.000 description 1
- 229940092253 ovalbumin Drugs 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229940068968 polysorbate 80 Drugs 0.000 description 1
- 229960000380 propiolactone Drugs 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 238000011897 real-time detection Methods 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 210000002345 respiratory system Anatomy 0.000 description 1
- IOVGROKTTNBUGK-SJCJKPOMSA-N ritodrine Chemical compound N([C@@H](C)[C@H](O)C=1C=CC(O)=CC=1)CCC1=CC=C(O)C=C1 IOVGROKTTNBUGK-SJCJKPOMSA-N 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 239000012090 serum-supplement Substances 0.000 description 1
- 208000003265 stomatitis Diseases 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000004114 suspension culture Methods 0.000 description 1
- RTKIYNMVFMVABJ-UHFFFAOYSA-L thimerosal Chemical compound [Na+].CC[Hg]SC1=CC=CC=C1C([O-])=O RTKIYNMVFMVABJ-UHFFFAOYSA-L 0.000 description 1
- 229960004906 thiomersal Drugs 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- STCOOQWBFONSKY-UHFFFAOYSA-N tributyl phosphate Chemical compound CCCCOP(=O)(OCCCC)OCCCC STCOOQWBFONSKY-UHFFFAOYSA-N 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 208000005925 vesicular stomatitis Diseases 0.000 description 1
- 230000029812 viral genome replication Effects 0.000 description 1
- 210000002845 virion Anatomy 0.000 description 1
- 239000000277 virosome Substances 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
- 238000002689 xenotransplantation Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/70—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving virus or bacteriophage
- C12Q1/701—Specific hybridization probes
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
- G01N33/56983—Viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16051—Methods of production or purification of viral material
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16211—Influenzavirus B, i.e. influenza B virus
- C12N2760/16234—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/005—Assays involving biological materials from specific organisms or of a specific nature from viruses
- G01N2333/08—RNA viruses
- G01N2333/11—Orthomyxoviridae, e.g. influenza virus
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Virology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Physics & Mathematics (AREA)
- General Engineering & Computer Science (AREA)
- Analytical Chemistry (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Biophysics (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA2890962A CA2890962A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04255471 | 2004-09-09 | ||
| EP04255471.7 | 2004-09-09 | ||
| PCT/IB2005/003266 WO2006027698A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2890962A Division CA2890962A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA2579859A1 CA2579859A1 (en) | 2006-03-16 |
| CA2579859C true CA2579859C (en) | 2015-12-08 |
Family
ID=35520177
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2579859A Expired - Fee Related CA2579859C (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
| CA2890962A Abandoned CA2890962A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA2890962A Abandoned CA2890962A1 (en) | 2004-09-09 | 2005-09-09 | Decreasing potential iatrogenic risks associated with influenza vaccines |
Country Status (15)
| Country | Link |
|---|---|
| US (6) | US8119337B2 (enExample) |
| EP (5) | EP2471551B1 (enExample) |
| JP (7) | JP2008512443A (enExample) |
| AT (2) | ATE488248T1 (enExample) |
| CA (2) | CA2579859C (enExample) |
| CY (3) | CY1111180T1 (enExample) |
| DE (3) | DE602005024827D1 (enExample) |
| DK (4) | DK2179744T3 (enExample) |
| ES (4) | ES2357752T3 (enExample) |
| HR (4) | HRP20100673T1 (enExample) |
| PL (4) | PL2179744T3 (enExample) |
| PT (4) | PT2578229E (enExample) |
| RS (3) | RS51665B (enExample) |
| SI (4) | SI2578229T1 (enExample) |
| WO (1) | WO2006027698A1 (enExample) |
Families Citing this family (67)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RS51665B (sr) | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa |
| ES2310062B1 (es) | 2005-07-15 | 2009-11-13 | Bionostra, S.L. | Particulas pseudovirales vacias quimericas derivadas del virus causante de la enfermedad de la bursitis infecciosa (ibdv), procedimiento de obtencion y aplicaciones. |
| ATE494906T1 (de) | 2005-11-01 | 2011-01-15 | Novartis Vaccines & Diagnostic | Von zellen stammende virale impfstoffe mit geringen mengen an rest-zell-dna |
| WO2007052055A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics Srl | Adjuvanted vaccines with non-virion antigens prepared from influenza viruses grown in cell culture |
| NZ594482A (en) | 2005-11-04 | 2012-11-30 | Novartis Vaccines & Diagnostic | Influenza vaccines with reduced amount of oil-in-water emulsion as adjuvant |
| KR20080069232A (ko) | 2005-11-04 | 2008-07-25 | 노바티스 백신즈 앤드 다이아그노스틱스 에스.알.엘. | 스플리트 인플루엔자 백신에 대한 보조제로서 유리 수성상계면활성제를 갖는 에멀젼 |
| CA2628424A1 (en) | 2005-11-04 | 2007-05-10 | Novartis Vaccines And Diagnostics S.R.L. | Adjuvanted influenza vaccines including cytokine-inducing agents |
| ES2377884T3 (es) | 2005-11-04 | 2012-04-02 | Novartis Vaccines And Diagnostics S.R.L. | Vacunas contra la gripe que incluyen combinaciones de adyuvantes particulados e inmunopotenciadores |
| PL2478916T3 (pl) | 2006-01-27 | 2020-11-16 | Seqirus UK Limited | Szczepionki przeciw grypie zawierające hemaglutyninę i białka macierzy |
| WO2007110776A1 (en) | 2006-03-24 | 2007-10-04 | Novartis Vaccines And Diagnostics Gmbh & Co Kg | Storage of influenza vaccines without refrigeration |
| JP2009532352A (ja) | 2006-03-31 | 2009-09-10 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ワクチンのための高力価組み換えインフルエンザ・ウィルス |
| GB0614460D0 (en) | 2006-07-20 | 2006-08-30 | Novartis Ag | Vaccines |
| NZ575271A (en) * | 2006-09-11 | 2011-09-30 | Novartis Ag | Making influenza virus vaccines without using eggs |
| WO2008059018A2 (en) * | 2006-11-15 | 2008-05-22 | Intervet International B.V. | Vaccine for vaccinating felines and canines against influenza virus |
| JP2011506264A (ja) | 2006-12-06 | 2011-03-03 | ノバルティス アーゲー | インフルエンザウイルスの４つの株に由来する抗原を含むワクチン |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| PT2185191E (pt) | 2007-06-27 | 2012-11-27 | Novartis Ag | Vacinas contra a gripe com baixo teor de aditivos |
| GB0810305D0 (en) | 2008-06-05 | 2008-07-09 | Novartis Ag | Influenza vaccination |
| JP5518041B2 (ja) | 2008-03-18 | 2014-06-11 | ノバルティス アーゲー | インフルエンザウイルスワクチン抗原の調製における改良 |
| EP2361304A2 (en) | 2008-11-05 | 2011-08-31 | GlaxoSmithKline Biologicals S.A. | Novel method |
| EA023662B1 (ru) | 2009-02-10 | 2016-06-30 | Новартис Аг | Вакцины против гриппа со сниженным количеством сквалена |
| JP2012517416A (ja) | 2009-02-10 | 2012-08-02 | ノバルティス アーゲー | 増加した量のｈ３抗原を含むインフルエンザワクチン |
| WO2010092476A1 (en) | 2009-02-10 | 2010-08-19 | Novartis Ag | Influenza vaccine regimens for pandemic-associated strains |
| DE102010018462A1 (de) | 2009-04-27 | 2011-04-07 | Novartis Ag | Impfstoffe zum Schutz gegen Influenza |
| CN102695523A (zh) | 2009-09-10 | 2012-09-26 | 诺华有限公司 | 针对呼吸道疾病的组合疫苗 |
| JP2013507990A (ja) | 2009-10-26 | 2013-03-07 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | ベロ細胞において増強された複製を有する高力価の組換えインフルエンザウイルス |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| EP2566958B1 (en) * | 2010-05-03 | 2015-12-30 | GlaxoSmithKline Biologicals S.A. | Method for inactivating influenza virus |
| JP5876036B2 (ja) | 2010-05-21 | 2016-03-02 | ノバルティス アーゲー | インフルエンザウイルス再集合方法 |
| CA2801151A1 (en) | 2010-06-01 | 2011-12-08 | Novartis Ag | Concentration of vaccine antigens with lyophilization |
| PL2575872T3 (pl) | 2010-06-01 | 2021-02-22 | Seqirus UK Limited | Zatężanie antygenów szczepionkowych grypy bez liofilizacji |
| GB201011502D0 (en) | 2010-07-08 | 2010-08-25 | Glaxosmithkline Biolog Sa | Novel process |
| CA2808965C (en) | 2010-08-20 | 2020-01-07 | Theraject, Inc. | Soluble needle arrays for delivery of influenza vaccines |
| AU2011300402B2 (en) * | 2010-09-07 | 2015-01-22 | Novartis Ag | Generic assays for detection of mammalian reovirus |
| US9580761B2 (en) * | 2011-02-25 | 2017-02-28 | Novartis Ag | Exogenous internal positive control |
| ES2655051T3 (es) | 2011-08-26 | 2018-02-16 | Wisconsin Alumni Research Foundation | Virus de la gripe con segmento génico PB2 mutante como vacunas vivas atenuadas |
| EP2768528A1 (en) | 2011-10-20 | 2014-08-27 | Novartis AG | Adjuvanted influenza b virus vaccines for pediatric priming |
| EP2791680B1 (en) * | 2011-12-12 | 2015-12-09 | Novartis AG | Assay for influenza virus hemagglutinins |
| GB201218195D0 (en) | 2012-10-10 | 2012-11-21 | Istituto Zooprofilattico Sperimentale Delle Venezie | Composition |
| JP2016524915A (ja) | 2013-07-15 | 2016-08-22 | ウィスコンシン アルムニ リサーチ ファンデイション | Ｍｄｃｋ、ベロ細胞又は卵内で増強された複製を有する高力価の組換えインフルエンザウイルス |
| EP3105311A1 (en) | 2014-02-10 | 2016-12-21 | Univercells NV | System, apparatus and method for biomolecules production |
| RU2628800C2 (ru) * | 2014-03-12 | 2017-08-22 | Общество С Ограниченной Ответственностью "Фарминтерпрайсез" | Амидные соединения, способы получения, применение в качестве средств для лечения и профилактики заболеваний, вызываемых рнк-содержащими вирусами |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| AR102548A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y uso |
| AR102547A1 (es) | 2014-11-07 | 2017-03-08 | Takeda Vaccines Inc | Vacunas contra la enfermedad de manos, pies y boca y métodos de fabricación y su uso |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| KR20180035807A (ko) | 2015-06-26 | 2018-04-06 | 세퀴러스 유케이 리미티드 | 항원적으로 매치된 인플루엔자 백신 |
| WO2017007839A1 (en) | 2015-07-06 | 2017-01-12 | Wisconsin Alumni Research Foundation (Warf) | Improved influenza virus replication for vaccine development |
| AU2016290603B2 (en) | 2015-07-07 | 2022-06-02 | Seqirus UK Limited | Influenza potency assays |
| JP2019510481A (ja) | 2016-02-19 | 2019-04-18 | ウィスコンシン アルムニ リサーチ ファンデイション | ワクチン開発のための改善されたｂ型インフルエンザウイルス複製 |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| WO2019086463A1 (en) | 2017-10-30 | 2019-05-09 | Baxalta GmbH | Environmentally compatible detergents for inactivation of lipid-enveloped viruses |
| MY202505A (en) | 2017-11-03 | 2024-05-01 | Takeda Vaccines Inc | Zika vaccines and immunogenic compositions, and methods of using the same |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| US11389523B2 (en) | 2018-08-20 | 2022-07-19 | Wisconsin Alumni Research Foundation (Warf) | Vectors for eliciting immune responses to non-dominant epitopes in the hemagglutinin (HA) protein |
| JP2022514112A (ja) * | 2018-10-15 | 2022-02-09 | リジェネクスバイオ インコーポレイテッド | 複製欠損型ウイルスベクター及びウイルスの感染性を測定するための方法 |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| WO2020163804A1 (en) | 2019-02-08 | 2020-08-13 | Wisconsin Alumni Research Foundation (Warf) | Humanized cell line |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| AU2020269164B2 (en) | 2019-05-08 | 2024-04-04 | Takeda Vaccines, Inc. | Inactivated virus compositions and Zika vaccine formulations |
| WO2021041624A2 (en) | 2019-08-27 | 2021-03-04 | Yoshihiro Kawaoka | Recombinant influenza viruses with stabilized ha for replication in eggs |
| EP4061930A1 (en) | 2019-11-18 | 2022-09-28 | Seqirus Pty Ltd | Method for producing reassortant influenza viruses |
| JP2023511444A (ja) * | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
| WO2022187230A2 (en) * | 2021-03-01 | 2022-09-09 | Iowa State University Research Foundation, Inc. | Methods and compositions for detecting and producing porcine morbillivirus and immunogenic compositions thereof |
| CN114107392A (zh) * | 2021-11-22 | 2022-03-01 | 昆明理工大学 | 一种cvb5病毒类病毒样颗粒的制备方法 |
| US20250381261A1 (en) | 2022-02-09 | 2025-12-18 | Takeda Vaccines, Inc. | Zika vaccines and immunogenic compositions, and methods of using the same |
Family Cites Families (38)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4193991A (en) * | 1978-12-20 | 1980-03-18 | Cornell Research Foundation, Inc. | Canine parvovirus vaccine |
| EP0261955A3 (en) * | 1986-09-26 | 1989-06-07 | E.I. Du Pont De Nemours And Company | Process for immobilization of dna |
| US6284492B1 (en) * | 1988-02-26 | 2001-09-04 | Large Scale Biology Corporation | Recombinant animal viral nucleic acids |
| CA2054228A1 (en) | 1990-10-30 | 1992-05-01 | Masaharu Oki | Muramyldipeptide derivatives and influenza vaccine comprising the derivatives |
| JPH0813753B2 (ja) * | 1992-05-22 | 1996-02-14 | 株式会社微生物化学研究所 | 牛伝染性鼻気管炎ウイルス感染症、牛ウイルス性下痢−粘膜病ウイルス感染症、パラインフルエンザ３型ウイルス感染症、牛ｒｓウイルス感染症および牛アデノ７型ウイルス感染症５種混合生ワクチン |
| IL103939A (en) * | 1992-12-01 | 1996-09-12 | Abic Ltd | An anti-DBI vaccine in birds containing attenuated live DBI virus |
| CA2156525A1 (en) | 1993-02-19 | 1994-09-01 | Susan Dillon | Influenza vaccine compositions containing 3-o-deacylated monophosphoryl lipid a |
| DE4311580C1 (de) * | 1993-04-12 | 1994-08-18 | Werner Prof Dr Med Reutter | Glycoproteine, Verfahren zu ihrer Herstellung und sie enthaltende pharmazeutische Mittel |
| US5824536A (en) * | 1994-08-23 | 1998-10-20 | St. Jude Children's Research Hospital | Influenza virus replicated in mammalian cell culture and vaccine production |
| US6146873A (en) * | 1994-11-10 | 2000-11-14 | Baxter Aktiengesellschaft | Production of orthomyxoviruses in monkey kidney cells using protein-free media |
| ATE542891T1 (de) | 1994-11-10 | 2012-02-15 | Baxter Healthcare Sa | Verfahren zur herstellung von biologischen produkten in protein-freier kultur |
| GB9500788D0 (en) | 1995-01-16 | 1995-03-08 | Medeva Holdings Bv | Vaccine compositions |
| DE19612966B4 (de) | 1996-04-01 | 2009-12-10 | Novartis Vaccines And Diagnostics Gmbh & Co. Kg | MDCK-Zellen und Verfahren zur Vermehrung von Influenzaviren |
| DE19612967A1 (de) * | 1996-04-01 | 1997-10-02 | Behringwerke Ag | Verfahren zur Vermehrung von Influenzaviren in Zellkultur, sowie die durch das Verfahren erhältlichen Influenzaviren |
| TW570803B (en) | 1997-04-09 | 2004-01-11 | Duphar Int Res | Influenza vaccine |
| JPH1175833A (ja) * | 1997-06-23 | 1999-03-23 | Chemo Sero Therapeut Res Inst | トリレオウイルスの調製法 |
| GB9725084D0 (en) | 1997-11-28 | 1998-01-28 | Medeva Europ Ltd | Vaccine compositions |
| JP3795751B2 (ja) * | 1997-12-11 | 2006-07-12 | ユニバーシティ オブ サスカッチェワン | ブタからの離乳後多全身系消耗症候群ウイルス |
| GB9804632D0 (en) * | 1998-03-05 | 1998-04-29 | Cantab Pharma Res | Virus preparations and methods |
| AT408615B (de) | 1998-09-15 | 2002-01-25 | Immuno Ag | Neue influenzavirus-impfstoffzusammensetzung |
| US6855544B1 (en) * | 1999-04-15 | 2005-02-15 | Crucell Holland B.V. | Recombinant protein production in a human cell |
| GB9923176D0 (en) | 1999-09-30 | 1999-12-01 | Smithkline Beecham Biolog | Novel composition |
| EP1103610A1 (en) * | 1999-11-26 | 2001-05-30 | Introgene B.V. | Production of vaccines from immortalised mammalian cell lines |
| US7192759B1 (en) * | 1999-11-26 | 2007-03-20 | Crucell Holland B.V. | Production of vaccines |
| DOP2000000109A (es) * | 1999-12-23 | 2002-08-30 | Gerald Kleymann | Derivados de tiazolilamida |
| MY134424A (en) | 2001-05-30 | 2007-12-31 | Saechsisches Serumwerk | Stable influenza virus preparations with low or no amount of thiomersal |
| DE10144906B4 (de) | 2001-09-12 | 2013-11-28 | Novartis Vaccines And Diagnostics Gmbh | Verfahren zur großtechnischen Herstellung von Impfstoffen |
| DE10144903A1 (de) * | 2001-09-12 | 2003-03-27 | Chiron Behring Gmbh & Co | Vermehrung von Viren in Zellkultur |
| FR2836924B1 (fr) | 2002-03-08 | 2005-01-14 | Vivalis | Lignees de cellules aviaires utiles pour la production de substances d'interet |
| CN1678345B (zh) * | 2002-04-26 | 2013-09-11 | 米迪缪尼有限公司 | 制备流感病毒的多质粒系统 |
| DE10221836A1 (de) * | 2002-05-16 | 2003-12-04 | Lohmann Animal Health Gmbh | Attenuierung von Metapneumovirus |
| DK1520008T3 (da) * | 2002-07-09 | 2012-10-15 | Baxter Int | Medium frit for dyreprotein til dyrkning af celler |
| JP3957188B2 (ja) * | 2002-10-25 | 2007-08-15 | ▲あき▼夫 友田 | 抗ウィルス剤 |
| EP1596884A2 (en) | 2003-01-30 | 2005-11-23 | Medimmune, Inc. | Uses of integrin alphavbeta3 antagonists |
| CN101410519B (zh) * | 2003-04-25 | 2013-04-24 | 免疫医疗有限责任公司 | 间质肺病毒株及其在疫苗制剂中以及用作抗原性序列表达载体的用途和繁殖病毒的方法 |
| EP1528101A1 (en) | 2003-11-03 | 2005-05-04 | ProBioGen AG | Immortalized avian cell lines for virus production |
| RS51665B (sr) * | 2004-09-09 | 2011-10-31 | Novartis Vaccines And Diagnostics Gmbh. | Smanjenje potencijalnih jatrogenih rizika povezanih sa vakcinama protiv gripa |
| SG182206A1 (en) | 2007-06-14 | 2012-07-30 | Univ Oklahoma State | Vaccines containing canine parvovirus genetic variants |
-
2005
- 2005-09-09 RS RSP20110084 patent/RS51665B/sr unknown
- 2005-09-09 PT PT121930960T patent/PT2578229E/pt unknown
- 2005-09-09 DK DK09075377T patent/DK2179744T3/da active
- 2005-09-09 PL PL09075377T patent/PL2179744T3/pl unknown
- 2005-09-09 ES ES09075377T patent/ES2357752T3/es not_active Expired - Lifetime
- 2005-09-09 DK DK10075310T patent/DK2236155T3/da active
- 2005-09-09 SI SI200531776T patent/SI2578229T1/sl unknown
- 2005-09-09 EP EP12157945.2A patent/EP2471551B1/en not_active Expired - Lifetime
- 2005-09-09 PT PT10075310T patent/PT2236155E/pt unknown
- 2005-09-09 AT AT05795012T patent/ATE488248T1/de active
- 2005-09-09 ES ES10075310T patent/ES2386272T3/es not_active Expired - Lifetime
- 2005-09-09 DE DE602005024827T patent/DE602005024827D1/de not_active Expired - Lifetime
- 2005-09-09 CA CA2579859A patent/CA2579859C/en not_active Expired - Fee Related
- 2005-09-09 SI SI200531223T patent/SI1789084T1/sl unknown
- 2005-09-09 PL PL12193096T patent/PL2578229T3/pl unknown
- 2005-09-09 EP EP20090075377 patent/EP2179744B1/en not_active Expired - Lifetime
- 2005-09-09 AT AT09075377T patent/ATE489965T1/de active
- 2005-09-09 CA CA2890962A patent/CA2890962A1/en not_active Abandoned
- 2005-09-09 PL PL05795012T patent/PL1789084T3/pl unknown
- 2005-09-09 EP EP20120193096 patent/EP2578229B1/en not_active Revoked
- 2005-09-09 EP EP20100075310 patent/EP2236155B1/en not_active Revoked
- 2005-09-09 PL PL10075310T patent/PL2236155T3/pl unknown
- 2005-09-09 DE DE2021193096 patent/DE12193096T1/de active Pending
- 2005-09-09 RS RS20120317A patent/RS52400B/sr unknown
- 2005-09-09 US US11/662,481 patent/US8119337B2/en not_active Expired - Fee Related
- 2005-09-09 EP EP05795012A patent/EP1789084B1/en not_active Expired - Lifetime
- 2005-09-09 DE DE200560025170 patent/DE602005025170D1/de not_active Expired - Lifetime
- 2005-09-09 HR HR20100673T patent/HRP20100673T1/hr unknown
- 2005-09-09 SI SI200531234T patent/SI2179744T1/sl unknown
- 2005-09-09 ES ES05795012T patent/ES2357747T3/es not_active Expired - Lifetime
- 2005-09-09 SI SI200531559T patent/SI2236155T1/sl unknown
- 2005-09-09 PT PT05795012T patent/PT1789084E/pt unknown
- 2005-09-09 ES ES12193096T patent/ES2432655T3/es not_active Expired - Lifetime
- 2005-09-09 WO PCT/IB2005/003266 patent/WO2006027698A1/en not_active Ceased
- 2005-09-09 JP JP2007530801A patent/JP2008512443A/ja not_active Withdrawn
- 2005-09-09 DK DK05795012.3T patent/DK1789084T3/da active
- 2005-09-09 PT PT09075377T patent/PT2179744E/pt unknown
- 2005-09-09 RS RSP20110075 patent/RS51721B/sr unknown
- 2005-09-09 DK DK12193096T patent/DK2578229T3/da active
-
2011
- 2011-01-05 HR HR20110007T patent/HRP20110007T1/hr unknown
- 2011-02-09 CY CY20111100152T patent/CY1111180T1/el unknown
- 2011-02-16 CY CY20111100197T patent/CY1111208T1/el unknown
- 2011-07-19 JP JP2011158471A patent/JP2011207911A/ja not_active Withdrawn
- 2011-10-14 US US13/274,285 patent/US9220768B2/en not_active Expired - Fee Related
- 2011-11-08 JP JP2011244904A patent/JP2012025784A/ja not_active Withdrawn
-
2012
- 2012-08-07 CY CY20121100706T patent/CY1113225T1/el unknown
- 2012-08-07 HR HRP20120640TT patent/HRP20120640T1/hr unknown
-
2013
- 2013-01-10 US US13/738,929 patent/US8460914B2/en not_active Expired - Lifetime
- 2013-01-11 US US13/740,100 patent/US9358280B2/en not_active Expired - Fee Related
- 2013-02-20 JP JP2013030624A patent/JP2013100358A/ja not_active Withdrawn
- 2013-10-10 HR HRP20130962TT patent/HRP20130962T1/hr unknown
-
2015
- 2015-08-06 JP JP2015155818A patent/JP2015205929A/ja active Pending
-
2016
- 2016-05-09 US US15/150,214 patent/US10155932B2/en not_active Expired - Lifetime
- 2016-11-29 JP JP2016230896A patent/JP2017057209A/ja not_active Withdrawn
-
2018
- 2018-11-08 US US16/184,482 patent/US10954493B2/en not_active Expired - Lifetime
-
2019
- 2019-08-08 JP JP2019146040A patent/JP2019210292A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10954493B2 (en) | Decreasing potential iatrogenic risks associated with influenza vaccines | |
| EP2497495B3 (en) | Making influenza virus vaccines without using eggs | |
| JP2008512443A5 (enExample) | ||
| HK1172565A (en) | Decreasing potential iatrogenic risks associated with influenza vaccines | |
| HK1144374B (en) | Decreasing potential latrogenic risks associated with influenza vaccines | |
| HK1105364B (en) | Decreasing potential iatrogenic risks associated with influenza vaccines |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request | ||
| MKLA | Lapsed |
Effective date: 20180910 |